Medtech company Propiro earned FDA clearance for its Picasso feature within its Paradigm platform, according to a Jan. 15 news release.
Picasso works in Propiro’s AI platform, which provides continuous 3D measurements to help spine surgeons assess alignment intraoperatively.
“As intraoperative measurement becomes more practical, surgeons are looking for tools that let them assess progress while they are operating, not after the fact,” Gabriel Jones, CEO and cofounder, said in the release. “Picasso extends Paradigm’s existing 3D guidance capabilities by giving surgeons more direct control over registration at the point of care.”
This is the fourth FDA clearance that Propiro has earned.
